Mitchell E. Gross, MD, PhD

Associate Professor of Clinical Medicine

Image of Mitchell E. Gross, MD, PhD
Is this your profile? Click to edit

Overview

Dr. Gross is research director of the USC Norris Westside Cancer Center and the Center for Applied Molecular Medicine. His overall research interest focuses on applying modern techniques relating to the study of genes and proteins (genomics and proteomics) on the clinical problems faced in treating patients with prostate cancer. A particular interest relates to the androgen receptor and relating proteins and pathways as key driving forces behind the development and treatment of prostate cancer. As a medical oncologist, his clinical activities are focused on therapeutic clinical trials incorporating both molecularly targeted and conventional therapies to the care of patients with prostate cancer. He serves as primary investigator on many multi-center phase 1 and 2 clinical trials

Dr. Gross has earned degrees from the University of California, San Diego (B.A.), Baylor College of Medicine in Houston (M.D.), and the University of California, Los Angeles (Ph.D. Molecular Biology). He completed a residency in internal medicine and a fellowship in hematology and medical oncology at the UCLA Center for the Health Sciences.

Awards

  • Phi Beta Kappa, 1989
  • UCSD/Revelle College Academic: Leadership Award, 1990
  • Alpha Omega Alpha, 1994
  • Hewlett Packard Award for Excellence in Internal Medicine, 1994
  • Specialty Training Advanced Research Fellowship, 1997
     – 2002
  • Amgen Fellowship Research Award, 1999
  • Rhone Phoulenc Rorer Travel Award, 1999
  • AACR-AFLAC Scholar in Training Award,, 2001
  • Donna and Jesse Garber Award, 2006

Research Funding

  • Selective Cancer Treatment Based on High Frequency Ultrasonic Beam
    NIH · R21EB022932 · Sep 16, 2016 – Jul 31, 2018 · Role: Co-Principal Investigator
  • Role of PIASy in Androgen Signaling and Prostate Cancer
    NIH · K08DK064379 · Aug 21, 2002 – Jun 30, 2007 · Role: Principal Investigator

Publications

  • Intolerance of uncertainty, cognitive complaints, and cancer-related distress in prostate cancer survivors. Psychooncology. 2015 Feb; 24(2):228-35.. View in PubMed
  • Phase I/II trial of orteronel (TAK-700)–an investigational 17,20-lyase inhibitor–in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2014 Mar 01; 20(5):1335-44.. View in PubMed
  • Prostate cancer: Age is nothing but a number. Nat Rev Urol. 2013 12; 10(12):683-4.. View in PubMed
  • Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. Prostate. 2013 Feb 15; 73(3):306-15.. View in PubMed
  • Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med. 2012 Jul; 37(7):637-43.. View in PubMed
  • Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer. Clin Genitourin Cancer. 2012 Dec; 10(4):232-8.. View in PubMed
  • Multimodality imaging in biochemical recurrence of prostate cancer: utility of (18)F-NaF PET/CT in early detection of metastasis. Rev Esp Med Nucl Imagen Mol. 2012 Jul-Aug; 31(4):231-2.. View in PubMed
  • Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol. 2012 Jul; 62(1):55-63.. View in PubMed
  • Body image predicts quality of life in men with prostate cancer. Psychooncology. 2013 Apr; 22(4):756-61.. View in PubMed
  • Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition. Mol Cancer Ther. 2012 May; 11(5):1071-81.. View in PubMed